Patents by Inventor Martin Pulé

Martin Pulé has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240384278
    Abstract: The present invention provides a nucleic acid construct comprising: a first nucleotide sequence of interest (NOI1); a frame-slip motif or a translational readthrough motif (FSM/TRM); and a second nucleotide sequence of interest (NOI2). The invention also provides vectors and cells expressing such a construct. The invention also provides a method for modulating the relative expression of two transgenes in a nucleic acid construct which comprises the step of including a frame-slip motif or a translational readthrough motif between the two transgenes in order to reduce the expression of the downstream transgene.
    Type: Application
    Filed: February 28, 2024
    Publication date: November 21, 2024
    Inventors: Shaun Cordoba, James Silliboume, Martin Pulè
  • Publication number: 20240374727
    Abstract: The present invention relates to CCR9 binding domains. In particular, the invention provides chimeric antigen receptors (CARs) comprising such CCR9 binding domains.
    Type: Application
    Filed: September 9, 2022
    Publication date: November 14, 2024
    Inventors: Marc Mansour, Martin Pulé, Paul Maciocia, Patrycja Wawrzyniecka
  • Publication number: 20240309400
    Abstract: The present invention provides a kit of vectors for transducing an immune cell with multiple transgenes comprising: (i) a first vector which comprises a first transgene and a nucleotide sequence encoding a transcription factor and; and (ii) a second vector which comprises a second transgene wherein expression of the second transgene within a host cell is dependent upon expression of the transcription factor.
    Type: Application
    Filed: November 8, 2023
    Publication date: September 19, 2024
    Inventors: Martin Pulé, James Sillibourne, Shaun Cordoba
  • Publication number: 20240307440
    Abstract: The present invention provides a cell which comprises a first exogenous nucleic acid molecule encoding a Chimeric Antigen Receptor (CAR) and a second exogenous nucleic acid molecule encoding a transcription factor.
    Type: Application
    Filed: November 30, 2023
    Publication date: September 19, 2024
    Inventors: Martin Pulé, Simon Thomas, Shaun Cordoba, Wen Chean Lim
  • Publication number: 20240301088
    Abstract: Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises?a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:?b) a light chain variable region (VL) having CDRs with the following sequences: T cells expressing such a CAR are useful in the treatment of some cancers.
    Type: Application
    Filed: November 21, 2023
    Publication date: September 12, 2024
    Inventors: Martin Pulé, John Anderson, Simon Thomas
  • Patent number: 12049510
    Abstract: The present invention provides a chimeric antigen receptor (CAR) which binds a low density target antigen, which comprises a Fab antigen binding domain. The invention also relates to cells expressing such a CAR and their use in the treatment of disease.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: July 30, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Simon Thomas, Shimobi Onuoha, Mathieu Ferrari, Wen Chean Lim, Biao Ma
  • Publication number: 20240166996
    Abstract: The invention relates to a method comprising (a) providing a vertebrate somatic cell, (b) inducing expression in said cell of at least three transcription factors, wherein said transcription factors are: i. Tbet (Tbx21), ii. Tcf7, and iii. Ets1; (c) incubating said cell to allow transdifferentiation. Suitably said cell is transdifferentiated to an immune effector cell. The invention also relates to cells, nucleic acids, pharmaceutical compositions, and methods of treatment.
    Type: Application
    Filed: March 4, 2022
    Publication date: May 23, 2024
    Inventors: Carlos Fillipe Ribeiro Lemos Pereira, Martin Pulé
  • Publication number: 20240158500
    Abstract: The present invention provides CD160 binding domains. The invention also relates to antibodies or fragments thereof, chimeric antigen receptors (CARs) and bi-specific T cell engagers (BiTEs) which comprise such binding domains.
    Type: Application
    Filed: November 4, 2021
    Publication date: May 16, 2024
    Inventors: Samir Agrawal, Martin Pulé, Francesco Nannini
  • Publication number: 20240156926
    Abstract: The present invention provides a polypeptide having the formula: St—R1—S1—Q—S2—R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd10-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd10-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer.
    Type: Application
    Filed: April 18, 2023
    Publication date: May 16, 2024
    Inventors: Martin Pulé, Brian Philip
  • Patent number: 11982672
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: May 14, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Paul Maciocia
  • Patent number: 11982673
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: May 14, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Paul Maciocia
  • Patent number: 11963981
    Abstract: The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: April 23, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Evangelia Kokalaki, Shaun Cordoba, Shimobi Onuoha, Simon Thomas, Biao Ma, Mathieu Ferrari
  • Patent number: 11965173
    Abstract: There is provided a plasmid system for transfection into a cell to create a producer cell, the system comprising: a. a helper plasmid comprising a first nucleotide sequence encoding Murine leukemia virus (MLV)-derived Gag and Pol poly-proteins; b. an envelope plasmid comprising a second nucleotide sequence encoding an Env protein; c. a genome plasmid comprising a third nucleotide sequence encoding a retroviral genome, wherein the first nucleotide sequence is codon-shuffled to remove any significant regions of homology with the third nucleotide sequence; and wherein the second nucleotide sequence is codon-optimised for expression in the producer cell.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 23, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Paulo Fernandes, Hanna Kymalainen, Ekaterini Kotsopoulou
  • Patent number: 11959084
    Abstract: The present invention provides a nucleic acid construct comprising: a first nucleotide sequence of interest (NOI1); a frame-slip motif or a translational readthrough motif (FSM/TRM); and a second nucleotide sequence of interest (NOI2). The invention also provides vectors and cells expressing such a construct. The invention also provides a method for modulating the relative expression of two transgenes in a nucleic acid construct which comprises the step of including a frame-slip motif or a translational readthrough motif between the two transgenes in order to reduce the expression of the downstream transgene.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: April 16, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Shaun Cordoba, James Sillibourne, Martin Pulé
  • Publication number: 20240117048
    Abstract: The present invention provides a polypeptide comprising: (i) a first domain which is capable of downregulating cell surface expression of an MHC class I molecule; and (ii) a second domain which is capable of binding to a target molecule.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 11, 2024
    Inventors: Paul Maciocia, Martin Pulé
  • Patent number: 11945867
    Abstract: The present invention provides antibodies and polyclonal antibody preparations which bind the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T-cell receptor constant region 1 (TRBC1). The antibodies can be used to determine whether a T-cell malignancy clonally expresses TRBC1 or TRBC2.
    Type: Grant
    Filed: December 21, 2019
    Date of Patent: April 2, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shimobi Onuoha, Ana Margarida Neves, Mathieu Ferrari, Paul Maciocia
  • Publication number: 20240093232
    Abstract: The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises a mitogenic T-cell activating transmembrane protein which comprises: (i) a mitogenic domain which binds a mitogenic tetraspanin, and (ii) a transmembrane domain; wherein the mitogenic T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells or Natural Killer cells are transduced by such a viral vector, they are activated by the mitogenic T-cell activating transmembrane protein.
    Type: Application
    Filed: January 26, 2023
    Publication date: March 21, 2024
    Inventors: Vijay Peddareddigari, Richard Beswick, John Short, Martin Pulé, Ekaterini Kotsopoulou
  • Publication number: 20240091357
    Abstract: The present invention relates to an engineered immune cell which comprises: (i) a target binding polypeptide comprising a target-binding domain and a first protein interaction domain, and (ii) a localising polypeptide comprising a second protein interaction domain, which binds to the first protein binding domain, and an intracellular retention signal. When the target binding polypeptide binds its target protein and also the localising polypeptide, expression of the target protein at the cell surface is reduced or eliminated because the target protein is retained in an intracellular compartment.
    Type: Application
    Filed: October 9, 2020
    Publication date: March 21, 2024
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas, Thomas Grothier
  • Publication number: 20240076352
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Application
    Filed: May 22, 2023
    Publication date: March 7, 2024
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Ben Draper
  • Publication number: 20240075066
    Abstract: The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.
    Type: Application
    Filed: May 24, 2023
    Publication date: March 7, 2024
    Inventors: Martin Pulé, Shaun Cordoba, Simon Thomas, Shimobi Onuoha, Matteo Righi